Ann: March 2014 NEWSLETTER , page-24

Now I can see clearly - damned Macintosh; PC works fine. Don't you hate it when the tech lets you down. Anyway, apologies for the little dummy spit.

And speaking of seeing things clearly, to me the Newsletter is the best yet at highlighting just what substantial opportunities are available to POH in the short, mid and (hopefully) not-too-long term.

These were the key messages I took from the Newsletter:

# Personal Care - GNC, BioElixia and Ashland /Vital ET continue to generate revenue (not sure just how much?).

# Animal Health
Royalty-based arrangements in place and Animal Health sector presents substantial opportunity to ramp up sales of TPM.
Animal feed expected to become a strong revenue contributor for POH.
Mastitis/USDA remains an unknown.

# Pain (Tier 2), i.e. Lidocaine patch, Diclofenac patch and gel, injectables (antibiotic, propofol), Tretinoin, Ketoconazole and multiple additional NSAID gels (under development).
POH is engaged in discussions with a number of pharma companies and this second tier of pain products is expected to provide worthy short to mid-term revenue opportunities - many with global prospects.

# Pain (Tier 1)
Oxymorphone and Oxycodone remain the big fish.

Did someone say something about getting rich one day?